This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01432/identifier/drugbank/
n24http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB01432/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n9http://www.rxlist.com/cgi/generic/
n4http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
n22http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n21http://www.drugs.com/cdi/
n18http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01432/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01432/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01432
rdf:type
n5:Drug
n5:description
Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.
n5:dosage
n20:271B4A4F-363D-11E5-9242-09173F13E4C5 n20:271B4A50-363D-11E5-9242-09173F13E4C5 n20:271B4A51-363D-11E5-9242-09173F13E4C5 n20:271B4A52-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
6 minutes
n5:indication
Indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Also for the relief of pruritus associated with partial biliary obstruction.
owl:sameAs
n4:DB01432 n24:DB01432
dcterms:title
Cholestyramine
adms:identifier
n7:DB01432 n14:0185-0940-97 n15:PA448974 n16:Cholestyramine
n5:mechanismOfAction
Cholestyramine binds bile in the gastrointestinal tract to prevent its reabsorption. The resin is a strong anion exchange resin, which means that it can exchange its chloride anions with anionic bile acids in the gastrointestinal tract and bind them strongly in the resin matrix. The functional group of the anion exchange resin is a quaternary ammonium group attached to an inert styrene-divinylbenzene copolymer.
n5:packager
n10:271B4A3E-363D-11E5-9242-09173F13E4C5 n10:271B4A3F-363D-11E5-9242-09173F13E4C5 n10:271B4A3C-363D-11E5-9242-09173F13E4C5 n10:271B4A3D-363D-11E5-9242-09173F13E4C5 n10:271B4A36-363D-11E5-9242-09173F13E4C5 n10:271B4A37-363D-11E5-9242-09173F13E4C5 n10:271B4A35-363D-11E5-9242-09173F13E4C5 n10:271B4A3A-363D-11E5-9242-09173F13E4C5 n10:271B4A3B-363D-11E5-9242-09173F13E4C5 n10:271B4A38-363D-11E5-9242-09173F13E4C5 n10:271B4A39-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces.
n5:synonym
Cholestyramine resin Colestyramine
n5:toxicity
Overdose may result in blockage of intestine or stomach.
n11:hasAHFSCode
n12:24-06-04
n5:foodInteraction
Take with food, do not mix with soft drinks.
n5:synthesisReference
Moh. S. Amer, Jack C. Gray, "Cholestyramine compositions and method for preparation thereof." U.S. Patent US4895723, issued March, 1967.
n22:hasConcept
n23:M0004278
foaf:page
n9:cholestyramine.htm n21:cholestyramine-powder.html
n5:Water-Solubility
n18:271B4A53-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n17:C10AC01
n5:absorption
Not absorbed from the gastrointestinal tract following oral administration.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
11041-12-6
n5:category
n5:containedIn
n13:271B4A4B-363D-11E5-9242-09173F13E4C5 n13:271B4A49-363D-11E5-9242-09173F13E4C5 n13:271B4A4A-363D-11E5-9242-09173F13E4C5 n13:271B4A43-363D-11E5-9242-09173F13E4C5 n13:271B4A44-363D-11E5-9242-09173F13E4C5 n13:271B4A41-363D-11E5-9242-09173F13E4C5 n13:271B4A42-363D-11E5-9242-09173F13E4C5 n13:271B4A47-363D-11E5-9242-09173F13E4C5 n13:271B4A48-363D-11E5-9242-09173F13E4C5 n13:271B4A45-363D-11E5-9242-09173F13E4C5 n13:271B4A46-363D-11E5-9242-09173F13E4C5 n13:271B4A40-363D-11E5-9242-09173F13E4C5 n13:271B4A4E-363D-11E5-9242-09173F13E4C5 n13:271B4A4C-363D-11E5-9242-09173F13E4C5 n13:271B4A4D-363D-11E5-9242-09173F13E4C5